Seres Therapeutics, Inc. — Form 8-K
Filed August 4, 2026 · analyzed by the 8-K Agent
8-K
▼ Likely negative
significance 72/100
What the filing says
Seres Therapeutics terminated its lease at 200 Sidney Street, Cambridge, MA (executed July 31, 2026, effective December 31, 2026). Payment to landlord BMR-Sidney Research Campus LLC comprises: (1) $2.24M letter-of-credit increase (total $3.64M, applied to rent through lease end); (2) $3.85M termination fee (due January 4, 2027); (3) 103,520 shares of common stock valued at $500K (share count calculated as $500K ÷ closing price on Nasdaq July 31, 2026, issued within 5 business days). Company retains 47,341 sq ft on three floors through December 31, 2026; AbbVie's 21,295 sq ft subleased space (floors 1 & 4) surrendered immediately. Total lease obligation reduction from ~68,636 sq ft to 47,341 sq ft.
Why this rating
~$6.6M total cash outlay ($2.24M + $3.85M + ~$500K equity value) against $71.9M market cap = 9.2% of company value. Real estate exit costs are material but single-event; non-recurring. Landlord compensation via equity reflects distressed negotiation.
See more from August 4, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.